The main objective of this publication is to make the reader aware of the complexity and steps that are necessary to make a Food and Drug Administration (FDA)-approved laboratory produced cell-based device, for use in clinical trials for reconstructive surgery. Most tissue-engineered cell-based devices are considered as ‘human somatic cell therapy’ and fall under the auspices of the Center of Biologic Evaluation and Research (CBER) and are considered a combination product by the FDA. We have illustrated the algorithm that is necessary to follow an Independent New Drug (IND) application by using our ex vivo produced oral mucosa equivalents (EVPOME), a tissue-engineered oral mucosa, as an example of a cell-based device that needs FDA approval prior to clinical application. By illustrating the experimental approach and presenting resulting data we attempt to explain each step that we address along the way.

Keywords:
Tissue engineering, Oral mucosa, Keratinocyte, Food and Drug Administration
1.
Bell, E. (1995) Strategy for the selection of scaffolds for tissue engineering. Tissue Eng 1: 163–179.
2.
Bell, E., H.P. Ehrlich, D.J. Buttle, T. Nakatsuji (1981) Living tissue formed in vitro and accepted as skin-equivalent tissue of full thickness. Science 211: 1052–1054.
3.
Boyce, S.T. (1996) Cultured skin substitutes: A review. Tissue Eng 2: 255–266.
4.
Clugston, P.A., C.F. Snelling, I.B. MacDonald, H.L. Maledy, J.C. Boyle, E. Germann, A.D. Courtemanche, P. Wirtz, D.J. Fitzpatrick, D.A. Kester, B. Foley, R.J. Warren, N.J. Carr (1991) Cultured epithelial autografts: Three years of clinical experience with eighteen patients. J Burn Care Rehabil 12: 533–539.
5.
Compton, C.C. (1993) Acceleration of skin regeneration from cultured epithelial autografts by transplantation to homograft dermis. J Burn Care Rehabil 14: 653–662.
6.
Du Moulin, G.C., M. Morohashi (2000) Development of a regulatory strategy for the cellular therapies: An American perspective. Mater Sci Eng C 13: 15–17.
7.
Gallico, G.G., N.E. O’Conner (1995) Engineering a skin replacement. Tissue Eng 1: 231–240.
8.
Gibbs, S., J. Vicanova, J. Bouwstra, D. Valstar, J. Kempenaar, M. Ponec (1997) Culture of reconstructed epidermis in a defined medium at 33 degrees C shows a delayed epidermal maturation, prolonged lifespan and improved stratum corneum. Arch Dermatol Res 289: 585–595.
9.
Hillerup, S. (1993) Grafting of skin and oral mucosa in the oral and maxillofacial regions; in MacIntosh, R.B. (ed): Oral and Maxillofacial Clinics of North America. Philadelphia, Saunders, vol. 5, pp. 557–577.
10.
Hinterhuber, G., Y. Marquardt, E. Diem, K. Rappersberger, K. Wolff, D. Foedinger (2002) Organotypic keratinocyte coculture using normal human serum: An immunomorphological study at light and electron microscopic levels. Exp Dermatol 11: 413–420.
11.
Inokuchi, S., K. Shimamura, H. Tohya, M. Kidokoro, M. Tanaka, Y. Ueyama, Y. Sawada (1995) Effects of fibroblasts of different origin on long-term maintenance of xenotransplanted human epidermal keratinocytes in immunodeficient mice. Cell Tissue Res 281: 223–229.
12.
Izumi, K., S.E. Feinberg (2002) Skin and oral mucosal substitutes; in Buckley, M.J., J.C. Keller (eds): Oral and Maxillofacial Clinics of North America. Philadelphia, Saunders, vol. 14, pp 61–71.
13.
Izumi, K., S.E. Feinberg, A. Iida, M. Yoshizawa (2003a) Intraoral grafting of an ex vivo produced oral mucosa equivalent: A preliminary report. Int J Oral Maxillofac Surg 32: 188–197.
14.
Izumi, K., G. Takacs, H. Terashi, S.E. Feinberg (1999) Ex vivo development of a composite human oral mucosal equivalent. J Oral Maxillofac Surg 57: 571–577.
15.
Izumi, K., H. Terashi, C.L. Marcelo, S.E. Feinberg (2000) Development and characterization of a tissue-engineered human oral mucosa equivalent produced in a serum-free culture system. J Dent Res 79: 798–805.
16.
Izumi, K., H. Terashi, C.L. Marcelo, S.E. Feinberg (2003b) Evaluation of transplanted tissue-engineered oral mucosa equivalents to SCID mice. Tissue Eng 9: 163–174.
17.
Kangesu, T., H.A. Navsaria, S. Manek, P.R. Fryer, I.M. Leigh, C.J. Green (1993) Kerato-dermal grafts: The importance of dermis for the in vivo growth of cultured keratinocytes. Br J Plast Surg 46: 401–409.
18.
Lee, D.Y., H.T. Ahn, K.H. Cho (2000) A new skin equivalent model: Dermal substrate that combines de-epidermized dermis with fibroblast-populated collagen matrix. J Dermatol Sci 23: 132–137.
19.
Marks, M.G., C. Doillon, F.H. Silver (1991) Effects of fibroblasts and basic fibroblast growth factor on facilitation of dermal wound healing by type I collagen matrices. J Biomed Mater Res 25: 683–696.
20.
Martin, G., M.C. Bene, N. Mole, J. Penaud, G.C. Faure, N.A. Miller (1995) Synthetic extracellular matrix supports healing of mucogingival surgery donor sites. Tissue Eng 1: 279–288.
21.
Monteiro-Riviere, N.A., A.O. Inman, T.H. Snider, J.A. Blank, D.W. Hobson (1997) Comparison of an in vitro skin model to normal human skin for dermatological research. Microsc Res Tech 37: 1331–1340.
22.
Mosmann, T. (1983) Rapid colorimetric assay for cellular growth and survival: Application to proliferation and cytotoxicity assays. J Immunol Methods 65: 55–63.
23.
Murphy, D.B., S.L. Epstein (1998) Guidance for industry: Guidance for human somatic cell therapy and gene therapy. Hum Gene Ther 12: 304–314.
24.
Nishiyama, T., S. Amano, M. Tsunenaga, K. Kadoya, A. Takeda, E. Adachi, R.E. Burgeson (2000) The importance of laminin 5 in the dermal-epidermal basement membrane. J Dermatol Sci 25 (suppl 1): S51–S59.
25.
Ojeh, N.O., J.D. Frame, H.A. Navsaria (2001) In vitro characterization of an artificial dermal scaffold. Tissue Eng 7: 457–472.
26.
Parenteau, N.L., C.M. Nolte, P. Bilbo, M. Rosenberg, L.M. Wilkins, E.W. Johnson, S. Watson, V.S. Mason, E. Bell (1991) Epidermis generated in vitro: Practical considerations and applications. J Cell Biochem 45: 245–251.
27.
Pomahac, B., T. Svensjo, F. Yao, H. Brown, E. Eriksson (1998) Tissue engineering of skin. Crit Rev Oral Biol Med 9: 333–344.
28.
Ralston, D.R., C. Layton, A.J. Dalley, S.G. Boyce, E. Freedlander, S. Mac Neil (1999) The requirement for basement membrane antigens in the production of human epidermal/dermal composites in vitro. Br J Dermatol 140: 605–615.
29.
Steel, M.P., B.J. Roessler (1999) Compliance with good manufacturing practices for facilities engaged in vector production, cell isolation, and genetic manipulations. Curr Opin Biotechnol 10: 295–297.
© 2004 S. Karger AG, Basel
2004
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.